Haleon PLC Executes Share Buyback to Strengthen Market Position

Haleon PLC ( (GB:HLN) ) has provided an announcement.

Haleon PLC announced the purchase and cancellation of 810,332 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction is part of Haleon’s strategy to manage its share capital and potentially enhance shareholder value, reflecting its commitment to maintaining a strong market position.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s strong financial health, strategic growth initiatives, and positive market momentum contribute to a robust stock outlook. While valuation metrics suggest caution due to higher P/E and modest dividend yield, the company’s strategic focus on innovation and market expansion, supported by recent corporate activities, reinforces investor confidence despite external challenges like currency fluctuations.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a portfolio that includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its well-known brands such as Advil, Centrum, and Sensodyne are built on trusted science and innovation.

Average Trading Volume: 27,931,455

Technical Sentiment Signal: Buy

Current Market Cap: £36.84B

Learn more about HLN stock on TipRanks’ Stock Analysis page.